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Abstract
Disorders of cobalamin (vitamin B12) metabolism are increasingly recognized in small
animal medicine and have a variety of causes ranging from chronic gastrointestinal
disease to hereditary defects in cobalamin metabolism. Measurement of serum cobal-
amin concentration, often in combination with serum folate concentration, is rou-
tinely performed as a diagnostic test in clinical practice. While the detection of
hypocobalaminemia has therapeutic implications, interpretation of cobalamin status
in dogs can be challenging. The aim of this review is to define hypocobalaminemia
and cobalamin deficiency, normocobalaminemia, and hypercobalaminemia in dogs,
describe known cobalamin deficiency states, breed predispositions in dogs, discuss
the different biomarkers of importance for evaluating cobalamin status in dogs, and
discuss the management of dogs with hypocobalaminemia.
K E YWORD S
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1 | INTRODUCTION
Disorders of cobalamin (vitamin B12) metabolism are increasingly recog-
nized in small animal medicine. Causes of cobalamin deficiency in dogs
vary from chronic gastrointestinal (GI) disease to hereditary defects in
cobalamin metabolism. Measurement of serum cobalamin concentra-
tion, often in combination with serum folate concentration, is routinely
performed as a diagnostic test in small animal practice to detect dogs
with vitamin B deficiency. The detection of hypocobalaminemia also
has therapeutic implications. Because interpretation of the cobalamin
status in dogs and the management of dogs with a suboptimal
cobalamin status can be challenging, an update on this topic and a defi-
nition of the different cobalamin states in dogs are provided here.
The aim of this review is to critically evaluate the veterinary
literature to define serum cobalamin status (normocobalaminemia,
hypocobalaminemia and cobalamin deficiency, and hypercobalaminemia),
describe causes of cobalamin deficiency states in dogs including breed
predispositions, summarize breed-specific changes in cobalamin metabo-
lism, discuss biomarkers of importance for evaluating cobalamin status in
dogs, and discuss the treatment options for dogs in which a suboptimal
or deficient cobalamin status has been diagnosed.
2 | COBALAMIN METABOLISM IN DOGS
2.1 | Ingestion and absorption of cobalamin
Cobalamin is a water-soluble vitamin, also referred to as vitamin B12.
It is mainly ingested with food of animal origin with liver, kidney, meat,
Abbreviations: AMN, amnionless; CIE, chronic inflammatory enteropathies; CUBN, cubilin;
EPI, exocrine pancreatic insufficiency; GC/MS, gas chromatography-mass spectrometry; GI,
gastrointestinal; HCY, homocysteine; IBD, inflammatory bowel disease; IF, intrinsic factor;
IGS, Imerslund-Gräsbeck syndrome; IRE, immunosuppressant-responsive enteropathy; LC/
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egg, milk products as well as fish having high cobalamin content, but
smaller amounts can also be produced by the intestinal microbiota.1
Plants and plant products contain virtually no cobalamin and,
whereas ruminants and other herbivores can produce a sufficient
amount of cobalamin in their intestines, omnivorous or carnivorous
animals including dogs and cats are not able to produce cobalamin.
The intestinal microbiota of dogs and cats can produce cobalamin in
the presence of cobalt, but because this site of cobalamin production
is distal to the site of its absorption, this ability appears to be of little
benefit to the animal. Most commercial pet foods, including vegan or
vegetarian diets, are supplemented with cobalamin,2,3 but the content
of dietary cobalamin varies between diets (dry diets: 0.05-0.25 mg/kg
dry matter basis; canned diets: 0.03-0.59 mg/kg dry matter basis).4
The National Research Council (NRC 2006) recommendation for
cobalamin fortification is 35 μg/kg dry matter for canine diets, regard-
less of the canine life stage.5 The concentration of serum cobalamin
and cobalamin-dependent metabolites is not related to the dogs being
fed a biologically appropriate raw food diet or a commercial dog
food.6 Bound to dietary protein, cobalamin reaches the stomach
where it is released by activated pepsinogen and gastric acid.7 Free
cobalamin is then bound to haptocorrin (R protein, transcobalamin I)
to protect it from bacterial utilization in the proximal GI tract.7 In the
duodenum, pancreatic proteases separate cobalamin from hap-
tocorrin, and free cobalamin is bound to intrinsic factor (IF). The major
site of IF synthesis is the gastric mucosa in humans, whereas in dogs
IF is produced primarily by the exocrine pancreas and to a lesser
extent in the stomach.8,9 The cobalamin-IF-complex is then absorbed
by receptor-mediated endocytosis. The receptor, known as cubam, is
localized at the brush border of the ileum (Fig. 1A and 2). This recep-
tor complex is comprised of 2 subunits, the proteins amnionless
(AMN) and cubilin (CUBN) (Fig. 1A and 2).10 In addition to receptor-
mediated cobalamin uptake at the ileal brush border epithelium,
approximately 1% of dietary cobalamin is absorbed via passive diffu-
sion across the intestinal mucosal epithelium, assumed to occur along
the entire length of the GI tract.11 Within the lysosomes of the
enterocytes, cobalamin is separated from IF and the receptor. Bound
to another transport protein, transcobalamin, cobalamin is then trans-
ported within the bloodstream to its target tissues. In humans, 20%-
30% of the cobalamin is bound to transcobalamin II, whereas most of
the circulating cobalamin (70%-80%) is bound to transcobalamin I and
thus unavailable for cellular uptake.12,13 Although transcobalamin II
appears to be much more abundant in dogs than in humans,
transcobalamin I exists in dogs.14 At the target tissue, cobalamin
enters the cells through specific receptors and is then released from
transcobalamin II (Fig. 1A).12 Approximately 15 μg/day of recirculating
cobalamin is extracted by hepatocytes and secreted in bile bound to
haptocorrin for enterohepatic recirculation.15 Within all eukaryotic
cells, cobalamin acts as an essential cofactor for the intracellular
enzymes methionine synthase and methylmalonyl-CoA mutase
(Fig. 3).16
F IGURE 1 Schematic of the
absorption of cobalamin by enterocytes in
the distal small intestine (ileum). A, In the
duodenum cobalamin is bound to intrinsic
factor (IF). The cobalamin-IF complex is
then absorbed by receptor-mediated
endocytosis. This cubam receptor is
localized at the brush border of the distal
small intestine (ileum). The receptor
complex is comprised of 2 subunits, the
proteins amnionless (AMN) and cubilin
(CUBN). Within the lysosomes of the
enterocytes, cobalamin is separated from
IF and the receptor. Bound to the
transport protein transcobalamin II,
cobalamin is then transported within the
bloodstream to its target tissues. A small
amount of circulating cobalamin is bound
to transcobalamin I and thus unavailable
for cellular uptake. Approximately 1% of
dietary cobalamin is absorbed via passive
diffusion across the intestinal mucosa. B,
Various disorders can impair cobalamin
metabolism
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2.2 | Intracellular function
2.2.1 | Methionine synthase
Methionine synthase, a cobalamin-, folate-, and pyridoxine (vitamin
B6)-dependent enzyme, catalyzes the regeneration of methionine
from homocysteine (HCY). This reaction links both cobalamin and
folate metabolism (Fig. 3). Disorders associated with a deficiency in
cellular cobalamin availability can thus lead to functional folate defi-
ciency states and increased serum concentrations of HCY
(hyperhomocysteinemia).
F IGURE 2 Immunofluorescent staining of the cobalamin receptor subunits in the canine ileum epithelium. The expression of the cobalamin
receptor was detected immunohistochemically in a cross section of an ileal villus from a dog using antibodies for the subunits (A) amnionless
(AMN, green) and (B) cubilin (CUBN, green). Both subunits are localized throughout the entire enterocyte (cell membrane and cytosol). Nuclei are
stained in blue with diamidine phenylindole (DAPI). The insert shows the corresponding secondary antibody control. Images were acquired using
equipment at the Laser Scanning Microscopy Core Facility (College of Veterinary Medicine, University of Leipzig, Germany)
F IGURE 3 Intracellular
pathways of cobalamin
metabolism. Methionine synthase
catalyzes the regeneration of
methionine from homocysteine.
Disorders associated with a
deficiency in cellular cobalamin
availability thus can lead to
functional folate deficiency and
increased concentrations of
homocysteine. Methylmalonic
CoA mutase catalyzes the
reaction from methylmalonyl
CoA to succinyl CoA which is a
key molecule in the tricarboxylic
acid cycle. A lack of intracellular
cobalamin leads to a reduced
enzyme activity and an
accumulation of methylmalonic
acid (MMA). Excess MMA is
excreted in the urine. MMA can
also inhibit the activity of
carbamoyl phosphate
synthetase I, an enzyme of the
urea cycle. Carbamoyl phosphate
synthetase I normally
metabolizes ammonia to
carbamoyl phosphate. When this
metabolic process is impaired,
plasma ammonia concentration
increases
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2.2.2 | Methylmalonyl-CoA mutase
Methylmalonyl-CoA mutase, a cobalamin-dependent enzyme, cata-
lyzes the formation of succinyl-CoA from methylmalonyl-CoA, which
is produced by the catabolism of odd-chain fatty acids and amino
acids (Fig. 3). Succinyl-CoA is a key molecule in the citric acid cycle. A
lack of intracellular cobalamin leads to a reduced enzyme activity and
an accumulation of methylmalonic acid (MMA) intracellularly and sub-
sequently also systemically (methylmalonic acidemia). On the one
hand, excess MMA undergoes urinary excretion (methylmalonic
aciduria); on the other hand, MMA can also inhibit the activity of car-
bamoyl phosphate synthetase I, an enzyme of the urea cycle. Car-
bamoyl phosphate synthetase I normally metabolizes ammonia to
carbamoyl phosphate. When this metabolic process is impaired,
plasma ammonia concentrations typically increase.1,17-20 Neurological
disorders can thus be a complication of cobalamin deficiency states in
dogs due to the increase in systemic MMA concentrations.1,17,18,21 In
humans, neurological symptoms also occur in organic acidemias
including methylmalonic acidemia.22
2.3 | Excretion of cobalamin
Body stores of cobalamin in dogs far exceed the amount of cobalamin
that is normally lost through the intestinal tract. Cobalamin undergoes
biliary excretion (bound to haptocorrin), and a large amount of cobala-
min is conserved by enterohepatic recirculation.1
Renal glomerular filtration of the transcobalamin II-cobalamin com-
plex is followed by tubular reabsorption to minimize urinary losses of
cobalamin. Megalin, an endocytic receptor in the proximal renal tubulus
that has a high affinity for the transcobalamin II-cobalamin complex,
mediates renal reabsorption and retention of cobalamin. Free cobala-
min is excreted in the urine.23,24 The cubam receptor is also present in
the kidneys25 and is involved in the renal reabsorption of several pro-
teins (eg, albumin, transferrin, and vitamin D-binding protein).
3 | LABORATORY TESTING TO EVALUATE
COBALAMIN STATUS
Subnormal serum cobalamin concentration or cellular cobalamin defi-
ciency in dogs can be detected by measuring serum cobalamin, HCY,
and MMA concentrations. Although serum cobalamin concentrations
are measured routinely in dogs and cats and determination of serum
cobalamin is offered by a number of veterinary diagnostic laborato-
ries, quantification of serum HCY and MMA is not routinely available,
although both are considered as useful markers to determine the cel-
lular cobalamin status of companion animals.7,26-28
3.1 | Laboratory tests
3.1.1 | Serum cobalamin concentration
There are several commercially available immunoassays for the mea-
surement of serum cobalamin concentrations. An automated chemilu-
minescence assay is routinely used in North America and Europe, and
the reference intervals (RI) for serum cobalamin concentrations in
dogs that are used by the different veterinary diagnostic laboratories
are similar (Table 1). An immunoassay is also available for measure-
ment of serum cobalamin concentrations in dogs but yields different
results than the chemiluminescent assay.29
The main indication for measuring serum cobalamin is to identify a
subnormal cobalamin status.30 Because cobalamin-dependent meta-
bolic reactions are localized to the intracellular compartment (ie, cyto-
plasm and mitochondria), the serum cobalamin concentration does
not necessarily exactly reflect the whole-body cobalamin status in an
individual dog. Intracellular storage of cobalamin is mostly as a cofac-
tor bound to cobalamin-dependent enzymes that might or might not
be saturated with cobalamin. Decreased liver and kidney cobalamin
stores, and certain defects in cobalamin metabolism, such as malab-
sorption due a defect in the ileal receptor, can result in cobalamin
deficiency. Therefore, other markers that more closely reflect the
intracellular availability of cobalamin such as the serum concentration
of HCY and MMA should ideally be included when assessing cobala-
min status.31 Cobalamin is stable in serum even if samples are not
strictly protected from light.32 Thus, in clinical practice, measurement
of serum cobalamin can be conveniently performed in serum samples
that are archived for up to 5 days. However, the long-term (>5 days)
stability of cobalamin in serum samples has not been reported.
3.1.2 | Serum HCY concentration
Serum HCY concentrations can be measured by gas chromatography-
mass spectrometry (GC/MS), with RIs of 5.0-22.1 μmol/L27 and
TABLE 1 Reference intervals (RIs) for serum cobalamin concentration
RI for serum cobalamin concentration Assay working range
Lower reference limit Upper reference limit Lower limit of quantification
Texas A&M University Gastrointestinal Laboratory 251 ng/L (185 pmol/L) 908 ng/L (670 pmol/L) 149 ng/L (110 pmol/L)
Idexx, Germany 317 ng/L (234 pmol/L) 1100 ng/L (812 pmol/L) 45 ng/L (33 pmol/L)
Synlab, Germany 299 ng/L (221 pmol/L) 801 ng/L (591 pmol/L) 150 ng/L (111 pmol/L)
Laboklin, Germany 301 ng/L (222 pmol/L) 802 ng/L (592 pmol/L) 50 ng/L (37 pmol/L)
Note: Shown are the RIs for serum cobalamin concentrations in dogs that have been established by 4 selected international veterinary diagnostic
laboratories. The RIs used by these 4 diagnostic laboratories are comparable.
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5.9-31.9 μmol/L.33 In human medicine, other methods that are used
for measuring HCY are a chemiluminescent microparticle immunoas-
say and an enzyme-cycling assay (Homocysteine Cobas C, Integra,
Roche).
Homocysteine is a sulfurated intermediate amino acid that is pro-
duced from dietary methionine and is then either remethylated to
methionine or metabolized to cysteine.34-36 Cobalamin (vitamin B12),
folic acid (vitamin B9), and pyridoxine (vitamin B6) are essential cofac-
tors for enzymes involved in the metabolism of HCY.37 Hyper-
homocysteinemia thus reflects an insufficient intracellular availability
of cobalamin, folic acid, or both for the synthesis of methionine, and
HCY is a sensitive marker for the detection of intracellular B vitamin
deficiency.37,38 Serum HCY concentrations increase early in the
course of cobalamin deficiency, and hyperhomocysteinemia can con-
tribute to the development of clinical signs caused by the decreased
availability of cobalamin for cellular metabolism.6 However, increased
serum or plasma HCY concentrations are less specific for intracellular
lack of cobalamin than is increased serum MMA concentrations.39
Serum HCY concentrations can also be increased with renal insuffi-
ciency40 or hypothyroidism.41
In humans, HCY has direct toxic effects on neurons and endothe-
lial cells, can induce DNA strand damage, oxidative stress, and apopto-
sis36,42 and also induce hepatic degeneration and fibrosis.43 Even
small changes in serum HCY concentrations (≥5-10 μmol/L) increase
the risk of cardiovascular diseases in people.36,37 Increased serum
HCY concentrations occur in dogs with cardiac or renal disease.44
Circulating HCY is mostly bound to albumin. As a consequence,
diseases associated with hypoalbuminemia, such as protein-losing
enteropathy (PLE), might be associated with a lower degree of hyper-
homocysteinemia than expected or even with
normohomocysteinemia.38,45 However, it is likely that breed-specific
effects exist. For example in Greyhounds,38 and breed-specific RIs for
serum HCY concentrations might need to be established because
other breeds of dog could also fail to show an association between
hypocobalaminemia and hyperhomocysteinemia. Preanalytical factors
are also important because serum HCY concentrations can be falsely
increased if the separation of red blood cells from serum is delayed.46
3.1.3 | Serum MMA concentration
Methylmalonic acid concentrations can be determined in serum and
urine samples. Serum MMA concentrations are measured routinely in
human medicine by either a GC/MS or liquid chromatography-tandem
mass spectrometry (LC/MS-MS) assay. However, measurement of
serum MMA concentrations is currently not routinely performed in
companion animals. RIs for serum MMA concentrations in dogs are
415-1,193 nmol/L (Texas A&M University Gastrointestinal Laboratory
[www.vetmed.tamu.edu/gilab]) and 393-1,476 nmol/L.47 Serum sam-
ples are needed for measuring cobalamin; thus, specimens collected
and used for serum chemistry analysis can also be used for measure-
ment of both cobalamin and MMA.
Because MMA production increases as a result of decreased intra-
cellular availability of cobalamin, MMA is a useful marker of cobalamin
deficiency at the cellular level. Such a deficiency can occur due to
cobalamin malabsorption, deficient cobalamin transport (which is not
reported in dogs), depletion of cobalamin stores in the liver and kid-
neys secondary to cobalamin malabsorption, or a combination of
these, leading to insufficient amounts of cobalamin entering the cells.
Tissues or cells with a high turnover rate such as enterocytes or blood
cells are primarily affected. Dogs with a serum cobalamin concentra-
tion below RI have significantly higher serum MMA concentrations
compared to dogs with normocobalaminemia, but serum MMA con-
centrations are increased in some (12%) normocobalaminemic dogs.26
In cobalamin-deficient Shar-Peis, where a suspected hereditary but
late-onset form of cobalamin deficiency with mostly signs of GI dis-
ease exists, serum MMA concentrations can even be 10 times higher
than in cobalamin-deficient dogs of other breeds.27
Careful interpretation of serum MMA concentrations should be
exercised in the presence of other conditions that can affect serum
MMA concentrations, such as renal insufficiency causing increased
serum MMA concentrations.48 Therefore, serum concentrations of
creatinine, symmetric dimethylarginine, or both should also be evalu-
ated when interpreting serum MMA concentrations.49 Other possible
causes for increased serum MMA concentrations, unrelated to pri-
mary cobalamin deficiency and renal disease, are dehydration, small
intestinal (SI) dysbiosis,26,50 and inherited defects of the enzyme sys-
tems involved in the metabolism of cobalamin and MMA. Inherited
etiologies also include defects in the absorption and transport of
cobalamin such as a deficiency of transcobalamin II. Such defects have
been reported in people, but further studies are needed to investigate
whether dogs are also affected by these.
Of healthy normocobalaminemic Border Collies, 38% have
increased urine MMA concentrations.6 None of these dogs have
increased serum HCY or decreased cobalamin concentrations com-
pared to cobalamin-deficient dogs. These cobalamin-deficient Border
Collies have a primary methylmalonic aciduria. However, bacterial
contamination of urine also has to be considered as a cause for
increased urinary MMA concentrations.47 A similar presentation
occurs in children with a defect in the methylmalonyl-CoA
mutase.37,51,52
Urine MMA concentrations are also measured by GC/MS26 or
LC/MS-MS.47 The RI was determined as 0-4.2 mmol/mol of creatinine
in 1 report.6 Dogs normally excrete <10 mg MMA/g of creatinine
(<9.6 mmol MMA/mol of creatinine).1 Normalizing urine MMA to cre-
atinine concentration minimizes the concentration or dilution effect
of urine on MMA concentrations. An advantage of measuring urinary
MMA concentration is easier determination because MMA concentra-
tions in urine are up to 40-fold higher than in serum. Furthermore,
MMA is stable in urine, and sample collection is less invasive com-
pared to the collection of blood samples.6
3.2 | Interpretation of cobalamin status
The currently recommended interpretation of the cobalamin status in
dogs is summarized in Table 2 (the cutoff serum cobalamin
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concentrations proposed below are based on the assay offered
through the Gastrointestinal laboratory at Texas A&M University)
and Fig. 4.
3.2.1 | Normocobalaminemia
Normocobalaminemia refers to a serum cobalamin concentration
within the RI for healthy dogs. However, serum cobalamin
concentration does not accurately reflect the cobalamin status on the
cellular level. If cobalamin transport into the cell is hindered, intracel-
lular cobalamin deficiency might result while the cobalamin concentra-
tion in serum remains within normal limits.53 In human medicine,
standard assessment of cobalamin status includes measurement of
serum cobalamin, HCY, MMA, and holotranscobalamin.54 Holo-
transcobalamin is the biologically active fraction of cobalamin that is
bound to transcobalamin II. A canine holotranscobalamin assay is cur-
rently not available; therefore, measurement of serum MMA and HCY
in addition to serum cobalamin is recommended (but currently not
widely available) to assess cobalamin status in dogs.
Twelve percent of dogs with chronic enteropathy and a serum
cobalamin concentration within the normal RI have an increased
serum MMA concentration.26 Twenty-two percent of dogs with
cobalamin close to the lower end of the RI have increased serum
MMA concentrations.33 These data suggest that a subtle or mild sub-
clinical intracellular cobalamin deficiency exists in these dogs. In
humans with suboptimal cobalamin status, the response to cobalamin
supplementation is a marked reduction in serum MMA concentra-
tion.55 Dogs with serum cobalamin concentrations at the lower end of
the RI have a normalization of serum MMA concentrations after
cobalamin supplementation.33 This could indicate that the discrepancy
between an increased serum MMA and a normal cobalamin concen-
tration reflects intracellular cobalamin deficiency despite that body
stores of cobalamin are sufficient to maintain normocobalaminemia.
Such a “cobalamin resistance” occurs in geriatric, diabetic, and hemo-
dialysis human patients.53 Alternative explanations could be the shift
to an increased pool of circulating cobalamin with hepatic disease53 or
a compromised translocation of cobalamin to the intracellular space
(which is not reported in dogs).
3.2.2 | Hypocobalaminemia
Hypocobalaminemia is typically referred to in dogs with a serum
cobalamin concentration between the lower limit of quantification
(LoQ) of the assay and the lower reference limit (Fig. 4). However,
careful interpretation is necessary because different laboratories use
different LoQs (Table 1).
Thirty-one percent of hypocobalaminemic dogs (as defined above)
have serum MMA concentrations above the RI,26 and these dogs are
assumed to be cobalamin-deficient on the cellular level. However, it is
TABLE 2 Evaluation of the cobalamin status in dogs
Cobalamin status
Normocobalaminemia Hypocobalaminemia Cobalamin deficiency Hypercobalaminemia
Serum cobalamin concentration Within RI # Below RI Undetectable " Above RI
Serum HCY concentration Within RI Within RI or " Above RI Within RI or " above RI Not reported
Serum MMA concentration Within RI# Within RI or " Above RI " Above RI Not reported
Note: # indicates decreased; " indicates increased.
Abbreviations: HCY, homocysteine; MMA, methylmalonic acid; RI, reference interval.
#Serum MMA concentration above RI might indicate insufficient intracellular (subclinical) cobalamin supply.
F IGURE 4 Interpretation of the cobalamin status in dogs.
Hypocobalaminemia is typically referred to as a serum cobalamin
concentration between the lower limit of quantification (LoQ) of the
assay and the lower reference limit. Dogs with cobalamin deficiency
have an undetectable serum cobalamin concentration (ie, below LoQ)
and a serum MMA concentration above RI. Cobalamin should be
supplemented whenever serum cobalamin concentration is
suboptimal (ie, less than approximately 400 ng/L)
6 KATHER ET AL.
possible that other factors (such as acute secondary SI dysbiosis due
to an acute flare of the underlying enteropathy, proton-pump inhibitor
use,56 or administration of oral antibiotics—Manchester AC, Blake A,
Webb C, Lidury J, Steiner J, Suchodolski J. Tylosin causes dysbiosis
associated with altered fecal unconjugated bile acids in healthy dogs.
Proceedings of the ACVIM Forum 2019, GI11 [abstract])57 contrib-
uted to the suboptimal serum cobalamin, but normal serum MMA
concentrations in the remaining 69% of dogs and that the
hypocobalaminemia in these dogs did not reflect a true whole-body
cobalamin deficiency. However, it remains to be determined whether
the hypocobalaminemia associated with SI dysbiosis correlates with
cobalamin deficiency at the cellular level.
After supplementation, cobalamin is rapidly extracted from plasma
by tissues where it binds to cobalamin-dependent enzymes with a rel-
atively long half-life.58 Thus, it is possible that the half-life of cobala-
min that is bound intracellularly as a coenzyme exceeds the residence
time of cobalamin within the circulation, which would mean that
cobalamin continues to be active in the tissues and cobalamin-
dependent metabolic processes are able to occur despite low serum
cobalamin concentrations. This is often observed in the treatment of
dogs with inherited disorders of cobalamin metabolism.59
3.2.3 | Cobalamin deficiency
The term cobalamin deficiency is not well-defined in the veterinary lit-
erature. Most current cobalamin assays have an LoQ between 45 and
150 ng/L (Table 1). We propose using the term cobalamin deficiency
for dogs with an undetectable serum cobalamin concentration and a
serum MMA concentration above RI (Table 2, Figure 4).
Sixty-three percent of dogs with undetectable serum cobalamin
concentrations have increased serum MMA concentrations indicating
cellular cobalamin deficiency.26 Normal serum MMA concentrations
in the remaining 37% of dogs with an undetectable serum cobalamin
concentration might suggest that a sufficient amount of cobalamin as
a cofactor is bound to cobalamin-dependent enzymes and a normal
activity of these enzyme is maintained in these dogs, whereas cobala-
min concentrations in the circulation are already severely decreased
because of their much shorter half-life.58 Therefore, measurement of
serum cobalamin concentration alone is not sufficient to diagnose or
exclude intracellular cobalamin deficiency, and determination of
serum MMA (and HCY) is recommended in addition to serum cobala-
min concentration.
3.2.4 | Hypercobalaminemia
Hypercobalaminemia refers to a serum cobalamin concentration
above the normal RI. Until recently, hypercobalaminemia was consid-
ered as a benign finding and was basically ignored in companion ani-
mals. However, recent data in people suggest that
hypercobalaminemia is an underestimated finding that can reflect a
number of serious underlying diseases such as solid neoplasms, hema-
tological and other malignancies, and hepatic or renal diseases.60-62
Abnormally high serum cobalamin concentrations occur in cats with
hepatic and neoplastic diseases.63 A retrospective analysis of the
medical records and data from 592 dogs that were presented for fur-
ther diagnostic workup at the University of Leipzig Small Animal Clinic
showed that 2% (n = 11) of all dogs in which serum cobalamin status
was determined and that did not receive any supplemental cobalamin
(n=487 dogs) had a serum cobalamin concentration above RI, ranging
from 1,100-3,561 ng/L (median: 1,334 ng/L) (unpublished data).
These hypercobalaminemic dogs had mostly (73%) signs of chronic GI
disease, and a neoplastic condition could not be definitively excluded
in 82% of the dogs. These findings suggest that hypercobalaminemia
is less frequently observed in dogs than in cats,63 in which a preva-
lence of 14% (28 of 202 cats) was observed in the study above
(unpublished data), and that hypercobalaminemia might be of clinical
relevance in dogs that have not received supplemental cobalamin. A
higher prevalence (36%) of hypercobalaminemia is reported
(Bertolani C, Tabar MD, Esparza A, et al. Hypercobalaminemia in
144 samples from cats and dogs. J Vet Intern Med. 2019;33
(2):1070-1071 [abstract]) in a smaller number of dogs with clinical
signs similar to those reported above (unpublished data), the upper
reference limit in which was also much lower (590 ng/L) which might
at least in part explain the discrepancy between the reported preva-
lence of hypercobalaminemia in dogs. Measurement of serum cobala-
min concentrations at 2 different laboratories also needs to be
considered when comparing the prevalence of hypercobalaminemia
between these 2 studies. Serum MMA concentrations have not been
evaluated in dogs with hypercobalaminemia.
4 | CONDITIONS ASSOCIATED WITH A
SUBOPTIMAL COBALAMIN STATUS
Hypocobalaminemia and cobalamin deficiency can have a variety of
causes in dogs including exocrine pancreatic insufficiency (EPI),
chronic severe ileal disease (eg, infiltrative disorders such as idiopathic
inflammatory bowel disease [IBD], alimentary lymphoma, or GI histo-
plasmosis), SI dysbiosis (though this condition is rarely definitively
diagnosed as the acquisition and analysis of the SI microbiota is cum-
bersome and invasive), and inherited conditions (Fig. 1B).49,64-71
Hypocobalaminemia also occurs in people with IBD (Crohn's disease
and ulcerative colitis). There are no reported cases of cobalamin defi-
ciency of dietary origin in dogs.31
4.1 | Clinicopathological findings and clinical
presentation
Blood cell count abnormalities, typically nonregenerative anemia with
megaloblastosis, neutropenia, and hypersegmented neutrophils, can
be early signs of derangements in cobalamin metabolism.72 With pro-
gression, disorders of phospholipid and amino acid metabolism have
been documented in other species and might also occur in dogs.21,73
In addition to blood cell dyscrasias and organic acidemias associ-
ated with neurological signs, especially dogs with hereditary cobala-
min deficiency can show severe clinical signs such as failure to thrive,
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anorexia, lethargy, vomiting, and diarrhea. The age of affected dogs at
presentation with clinically apparent disease also varies, with the
majority of dogs showing clinical signs early in life and a smaller pro-
portion of dogs having a more delayed onset of clinical signs.
4.2 | Hereditary conditions
A genetic background for cobalamin deficiency has been confirmed or
suspected in Giant Schnauzers,1,74 Border Collies,18,75-78 Chinese
Shar-Peis,79,80 Beagle dogs,17,59,81-83 Australian Shepherd dogs,19,25 a
Yorkshire Terrier,20 and also a mixed breed dog (Maguire D, Solano-
Gallego L, English K, et al. Cobalamin deficiency in a collie cross
Bedlington Terrier. Available at: https://www.esvcp.org/index.php/
docman/clin-path-cases/106-case-2-maguire-with-diagnosis/file.html);
genetic defects and hypocobalaminemia has been confirmed for a few
canine breeds. Certain dog breeds have a predisposition for
hypocobalaminemia for which the underlying mechanism or cause has
not been elucidated (see Section 4.2.1.). In some of these breeds,
cobalamin deficiency is a genetic trait. This condition is classified as a
hereditary or selective disorder in cobalamin metabolism (see
Section 4.2.2.). Finally, a genetic cause (eg, a specific mutation of the
cubam receptor) of selective cobalamin malabsorption was identified
or confirmed in some affected dog breeds (see Section 4.2.3). The cur-
rent literature is reviewed here, but it should be noted that additional
dog breeds might have a predisposition for cobalamin deficiency
because current studies do not cover an exhaustive list of geographi-
cal areas.
4.2.1 | Breed predispositions for hypocobalaminemia
and cobalamin deficiency
Serum concentrations of cobalamin have been used for many years in
veterinary practice to identify dogs with hypocobalaminemia or cobal-
amin deficiency, and 2 large surveys have been conducted with the
aim to identify canine breeds that might have a predisposition to
develop cobalamin deficiency.70,84
Test results of serum samples from 9,960 dogs submitted over a
13-year period to a laboratory in the United Kingdom were analyzed
to determine breed predispositions for hypocobalaminemia, hypo-
folatemia, or both.84 Breeds of dogs with an increased frequency of
hypocobalaminemia were the Chinese Shar-Pei, Staffordshire Bull
Terrier, German Shepherd Dog, and mixed breed dogs. Golden
Retrievers had a decreased odds ratio for being diagnosed with
hypocobalaminemia. There is an increased frequency of
hypocobalaminemia in Chinese Shar-Peis and German Shepherd Dogs
in North America.70 A high prevalence of severe hypocobalaminemia
in Stafford Bull Terriers and mixed breed dogs is reported in the
United Kingdom,84 but Staffordshire Bull Terriers do not have an
increased risk of hypocobalaminemia in the United States.70
In the North American study,70 serum cobalamin test results from
28,675 dogs of 164 breeds were reviewed to identify breeds with an
increased risk of being identified with hypocobalaminemia. This study
found Greyhounds to have the highest proportion of serum samples
submitted for cobalamin analysis and also the lowest serum cobalamin
concentrations compared to the other 18 breeds of dogs that were
significantly more likely to have a subnormal serum cobalamin con-
centration. This suggests that hypocobalaminemia or cobalamin defi-
ciency occurs frequently in this breed, which is supported by another
study indicating that Greyhounds frequently have hypofolatemia with
or without hypocobalaminemia.38 The high percentage of affected
dogs with hyperhomocysteinemia in this study suggests that cobala-
min deficiency is common in this breed.38 However, it is also possible
that normal serum cobalamin concentrations in Greyhounds are lower
than in dogs of other breeds, thus calling for a breed-specific RI. An
effect of exercise is unlikely because Greyhounds included in the
study were all retired racing dogs.38
4.2.2 | Selective cobalamin malabsorption
Selective cobalamin malabsorption is a rare congenital disease. The
first report about selective cobalamin malabsorption in dogs describes
2 related Giant Schnauzers that lacked the expression of the
cobalamin-IF-receptor complex in the apical brush border of the ileal
and renal epithelium.1 The human analog of this rare genetic disorder
is called Imerslund-Gräsbeck syndrome (IGS). Dogs with IGS are
unable to absorb dietary cobalamin.1,17,74
Classical clinical signs of IGS such as intermittent diarrhea, inappe-
tence, poor body condition, and failure to grow typically manifest
within the first year of age. Around that time fetal stores of cobalamin
are depleted while growth demands cobalamin to be utilized at high
rates. Dogs might be misdiagnosed because of the secondary effects of
hypocobalaminemia on metabolism such as the development of hypo-
glycemia, ketoacidosis, and hyperammonemia.18,19,78 Therefore, cobala-
min deficiency should be considered as a differential diagnosis in dogs
presented with a suspicion of a portosystemic shunt, hydrocephalus, or
metabolic disorders such as hypoglycemia and renal insufficiency.17
Another possible clinical manifestation of IGS is intermittent
impaired swallowing.76 Mucosal ulcerations might also develop,76,85
but glossitis, glossodynia, and stomatodynia are reported only in peo-
ple with cobalamin deficiency. Additionally, bradyarrhythmia is a pos-
sible clinical sign in dogs.76 Skin lesions (reversible hyperpigmentation)
occur in children with IGS.86
Hematologic abnormalities in human patients with IGS include a
dyshematopoesis that is typically characterized by a nonregenerative
anemia of varying severity and neutropenia. Microscopically, hyper-
segmented neutrophils may be noted. Megaloblastosis is rarely seen
in dogs,75 and some dogs with IGS present with a normal
hemogram.76 Although children with this disorder develop macrocytic
anemia, the anemia in dogs is usually normocytic and
normochromic.72,87-89 Thus, megaloblastic anemia does not appear to
be as closely associated with cobalamin deficiency in dogs as it is in
people. In affected dogs, both large and small red blood cells are pre-
sent systemically, resulting in an increased red cell distribution width
while the mean cellular volume remains within RI.72 Rarely, dogs with
IGS can present with Heinz body anemia caused by
hyperhomocysteinemia.78
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Breed-specific changes in serum cobalamin concentrations and
distinct clinical manifestations exist in the Border Collie, Beagle, and
Chinese Shar-Pei breeds (Table S1).
Border Collie
Several case reports and case series have described a selective cobala-
min malabsorption in the Border Collie breed.18,75,76,78 Clinical mani-
festations in some cases are mild and the onset of clinical signs can be
delayed into early adulthood compared to other breeds with selective
cobalamin malabsorption.17,75 Also, juvenile cobalamin deficiency
might not be routinely associated with hematologic changes in the
Border Collie breed.18,75,76
About 40% of healthy Border Collies have increased urine MMA
levels,6 but none of the normocobalaminemic dogs in that study had
increased plasma HCY concentrations compared to the Border Collies
with cobalamin deficiency. It has been hypothesized that these dogs
have a primary methylmalonic aciduria.6 Of note, hypocobalaminemia is
also associated with an increased prevalence of EPI in Border Collies.70
Beagle
Hereditary cobalamin malabsorption is reported in Beagle
dogs,17,59,85,90 and 2 Beagles with selective cobalamin malabsorption
developed degenerative liver disease.83 The hepatopathies seen in
these dogs might be associated with the chronic hyper-
homocysteinemia which was demonstrated to promote hepatic
inflammation and fibrosis in an experimental study in rats.43 Degener-
ative hepatopathies are also well described in farm animals, especially
in lambs and goats with decreased cobalt intake causing
hypocobalaminemia, but this etiology has not been reported in dogs
with hereditary cobalamin malabsorption.83
Decreased phagocytic activity has been demonstrated in human
patients with cobalamin deficiency.91 Cobalamin-deficient Beagle
dogs are suspected to be immunosuppressed, supporting the develop-
ment of complicating infections such as fungal hepatopathy or necro-
tizing pneumonia.78,81,92
Chinese Shar-Pei
Chinese Shar-Peis have a high prevalence of cobalamin deficiency
compared to other canine breeds.27,79,80,93 Even apparently healthy
Chinese Shar-Peis have increased serum MMA concentrations com-
pared to healthy dogs of other breeds, which led to the hypothesis
that some healthy Chinese Shar-Peis have subclinical cobalamin defi-
ciency.80 Cobalamin deficiency in Chinese Shar-Peis is also associated
with hyperhomocysteinemia.27 Clinical signs of affected dogs reflect
primarily an involvement of the GI tract with chronic signs of GI dis-
ease such as diarrhea, vomiting, and weight loss.93 Classical signs of
cobalamin deficiency such as hyperammonemia, hypoglycemia, and
seizures are typically lacking in these dogs.79
Hypocobalaminemia in Chinese Shar-Peis is not associated with
other common diseases in this breed such as cutaneous mucinosis or
Shar-Pei fever.93 However, evaluation of several biomarkers of inflam-
mation suggests the existence of an inflammatory phenotype in both
hypocobalaminemic and normocobalaminemic Chinese Shar-Peis.93
This might reflect compromised GI health in affected dogs, with the
result of a low-grade inflammation and malabsorption of vitamins such
as cobalamin.
Komondor
A recent study reported that selective cobalamin malabsorption is also
inherited via an autosomal recessive trait in Komondor dogs, an old
Hungarian herding dog breed.94
4.2.3 | Genetic causes of selective cobalamin
malabsorption
Each of the 2 subunits of the cubam receptor complex (ie, AMN and
CUBN) depends on the normal structure of the other part of the
receptor for epithelial brush border expression and function.81 Several
(close to 400) AMN and CUBN mutations occur in people with IGS. In
dogs, only 2 AMN mutations and 4 CUBN mutations have been identi-
fied to date.
Cubam expression is disrupted by 2 independent mutations in the
AMN gene in Australian Shepherd dogs and Giant Schnauzers.25 A
CUBN mutation causes IGS in Border Collies.77,95 A CUBN mutation is
also responsible for canine IGS in the Beagle breed.82 The CUBN
mutation in juvenile Beagle dogs causes more severe cobalamin mal-
absorption than a different CUBN defect in Border Collies81 and the
former condition to resemble more closely IGS caused by AMN muta-
tions in Giant Schnauzers and Australian Shepherd dogs. A residual
CUBN expression, which does not exist in affected Beagle dogs, might
explain why the diagnosis in some Border Collies can be delayed com-
pared to affected dogs of other breeds.81 Furthermore, in a study
including 200 randomly selected Border Collies, the frequency of dogs
being heterozygous for the CUBN mutation was relatively low at
6.2%,77 whereas increased carrier frequency has been noted in Bea-
gles, but the disease occurrence might be geographically depen-
dent.82,90 In Komondor dogs, a CUBN splice-site variant causes
cobalamin deficiency.94 Genetic tests have become commercially
available and allow for a diagnosis prior to the clinical manifestation of
the condition and also the detection of asymptomatic carriers to guide
breeding decisions (centerofanimalgenetics.com, animalabs.com, or
www.laboklin.de). A large genomic study in Chinese Shar-Peis rev-
ealed an association of 2 canine microsatellite markers, located on
canine chromosome 13, with cobalamin deficiency in this breed.79
However, there are no previously identified genes in this chromo-
somal region that are associated with cobalamin deficiency in dogs or
other species.79
4.3 | Gastrointestinal diseases
4.3.1 | Exocrine pancreatic insufficiency
Cobalamin deficiency is common in dogs with EPI. A study showed
82% of dogs with EPI have decreased serum cobalamin concentra-
tions, and 36% of these dogs had severe hypocobalaminemia (defined
as a serum cobalamin concentration of <100 ng/L in this study).66 A
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breed predisposition for EPI exists in German Shepherd Dogs, Rough
Coated Collies, Chow-Chows, Cavalier King Charles Spaniels, and
West Highland White Terriers, with German Shepherd Dogs rep-
resenting about 60% of all cases of EPI.66 Pancreatic acinar atrophy is
also an inherited disorder in the Eurasian breed.96
Exocrine pancreatic insufficiency is characterized by an inade-
quate production of digestive enzymes from pancreatic acinar cells,
leading to the typical clinical signs of weight loss in the face of poly-
phagia and increased fecal volume.97,98 Failure to absorb cobalamin in
dogs with EPI might be caused by 4 postulated or hypothetical mech-
anisms: pancreatic secretion of IF is reduced or absent, digestive
enzymes are lacking causing an impaired release of cobalamin from
haptocorrin and thus no binding of cobalamin to IF, secondary SI
dysbiosis compromising the endogenous production of cobalamin,
and the intestinal mucosa might also be compromised by the presence
of toxic metabolites due to SI dysbiosis.9,99-101 However, in people
cobalamin assimilation does not improve with antibiotic treatment,102
and there is no data that demonstrate a benefit of probiotics (eg,
Enterococcus faecium SF68103) or prebiotics.
Because the exocrine pancreas is the major site of IF synthesis in
dogs, cobalamin supplementation is often necessary in these dogs.
However, cobalamin deficiency in some cases is not corrected by
enzyme replacement alone likely because IF is not consistently a com-
ponent of the exogenous enzyme mixture.99 Treatment with bovine
pancreatic enzyme extract is also not sufficient to restore cobalamin
absorption in dogs with EPI, because IF appears to be species-specific.
The fact that serum cobalamin concentrations <100 ng/L are a nega-
tive prognostic factor66 underlines the importance to adequately sup-
plement dogs with EPI, but only 4 of 135 (3%) hypocobalaminemic
dogs with EPI were given supplemental cobalamin in that study.66
Another recent study revealed a prevalence of hypocobalaminemia
(serum cobalamin concentration <350 ng/L) of 55% in dogs with
EPI.104 Hypocobalaminemia was also shown to be a negative prognos-
tic factor in that study, and 112 of 116 dogs (82%) received cobalamin
supplementation.104
4.3.2 | Chronic inflammatory enteropathies
Chronic inflammatory enteropathies (CIE), further classified based on
the response to treatment as either food-responsive enteropathy,
antibiotic-responsive enteropathy, immunosuppressant-responsive
enteropathy (IRE), or nonresponsive enteropathy (NRE), are character-
ized by chronic persistent or recurrent clinical signs of GI disease
(such as vomiting, diarrhea, weight loss, or a combination of those) for
longer than 3 weeks and are diagnosed retrospectively based on the
response to treatment.65,71
It has been postulated that chronic mucosal disease affecting the
ileum reduces the epithelial expression or function of the cubam
receptor leading to a reduced mucosal uptake of cobalamin. However,
currently there are no studies that have investigated the expression
levels of the ileal cobalamin-IF-receptor in dogs with chronic
enteropathies.
In addition, cobalamin has been hypothesized to be decreased in
dogs with CIE because of secondary SI dysbiosis. Once the body
stores of cobalamin are depleted, cobalamin deficiency can occur.105
The half-life of cobalamin in healthy dogs is approximately
6-16 weeks.106 It is assumed that this half-life is decreased in dogs
with CIE as a result of a reduced cobalamin absorption in the face of
normal biliary excretion and enterohepatic circulation.49
Reported prevalences of hypocobalaminemia in dogs with CIE
ranged from 19% to 38%,49,65,107-110 and similar findings have been
reported in cats.111 Dogs with suboptimal serum cobalamin status
might not respond to treatment of the primary disease process unless
given supplemental cobalamin, because cobalamin is essential for
many cell functions and mucosal regeneration, and a deficiency can
contribute to mucosal inflammatory infiltration and villous
atrophy.72,105
Correlation of hypocobalaminemia with histopathologic findings
Histological lesions in dogs with CIE are often multifocally distributed,
and different degrees of disease severity might be found among the
different segments of the intestinal tract and also among different
regions within the same segment (Dossin O, Tesseydre JF, Concordet
D. Is duodenal mucosa representative of other small intestinal parts in
inflammatory bowel disease affected dogs? J Vet Intern Med.
2007;21:613 [abstract]).112-114 Because histological lesions of CIE
might be found in the ileum in the face of a normal duodenal mucosa,
ileal biopsies should be routinely collected in addition to duodenal
biopsies in all dogs with chronic signs of GI disease undergoing GI
endoscopy.113,114
Hypocobalaminemia correlates with an increased number of intra-
epithelial lymphocytes in the ileal mucosa,114 presenting evidence of
an association between ileal mucosal inflammatory changes and
hypocobalaminemia in dogs with CIE. However, the expression of the
cobalamin-receptor in dogs with CIE has not been evaluated.
Correlation of hypocobalaminemia with outcome in dogs
Several factors have been evaluated for their potential to predict out-
come in dogs with CIE.65 In addition to the presence of severe muco-
sal lesions in the duodenum and hypoalbuminemia (serum albumin
concentration of <20 g/L), hypocobalaminemia (defined as a serum
cobalamin concentration of <200 ng/L in this study) at the time of
diagnosis might predict refractoriness to treatment and was strongly
correlated with a negative outcome despite supplementation of cobal-
amin for 6 weeks.65 However, despite that hypocobalaminemia is a
negative prognostic factor, adequate supplementation of cobalamin
appears to be essential for the success of treatment. Thus, further
studies need to investigate if early initiation of cobalamin supplemen-
tation is associated with a better outcome in dogs with CIE.
Hypocobalaminemia also correlates with hypoalbuminemia in dogs
with CIE.65,108,109
Protein-losing enteropathy
Protein-losing enteropathy is a syndrome associated with an abnormal
loss of albumin into the intestinal lumen. Common causes for PLE are
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altered lymphatic drainage or increased mucosal permeability.69,115 A
predisposition for primary intestinal lymphangiectasia exists in Rott-
weilers, Yorkshire Terriers, Chinese Shar-Peis, Maltese, Norwegian
Lundehunds, Basenjis, Soft Coated Wheaten Terriers, and German
Shepherd Dogs.115-123 Secondary intestinal lymphangiectasia is asso-
ciated with mucosal inflammation in IRE/NRE, intestinal neoplasia, or
infectious diseases (eg, GI histoplasmosis) in dogs.69 Prevalences of
hypocobalaminemia range from 43%-75% in dogs with non-neoplas-
tic, noninfectious causes of PLE.65,107,124 Hypocobalaminemia was
also associated with decreased serum alpha1-proteinase inhibitor con-
centrations (presumably due to PLE) in Yorkshire Terriers.125
Serum cobalamin concentrations should be evaluated in all dogs
with PLE and, if needed, supplemental cobalamin be started early.69
4.3.3 | Alimentary lymphoma
Sixteen percent of dogs with multicentric lymphoma have
hypocobalaminemia, and this finding is associated with a poor out-
come.68 A higher rate of hypocobalaminemia (40% and 71%) is seen
in dogs with low-grade (lymphocytic) GI lymphoma.126,127 It is pre-
sumed that the hypocobalaminemia in dogs with lymphoma is a con-
sequence of the ileal infiltration with neoplastic lymphocytes
hypothetically resulting in a disruption of the receptor-mediated GI
uptake of cobalamin.68
4.3.4 | Small intestinal dysbiosis
Small intestinal (SI) dysbiosis is defined as an altered composition,
richness, or both of the intestinal microbiota.50
Competition between bacteria and host cells for essential nutri-
ents such as cobalamin can lead to malnutrition.67 Bacteroides spp. are
the principle competitors for cobalamin with the host because of the
ability to utilize cobalamin-IF complexes, in contrast to other bacteria
that can only bind free cobalamin.128 If these folate-producing bacte-
ria localize to the proximal intestine, an increased amount of folate of
bacterial origin can be absorbed by the host resulting in increased
serum folate concentrations.67 Hence, hypocobalaminemia with con-
current hyperfolatemia might suggest the presence of SI dysbiosis.
However, there are currently no studies using culture-independent
techniques that provide microbiological or ecological evidence of SI
dysbiosis associated with systemic hypocobalaminemia or hyper-
folatemia. The definitive diagnosis of SI dysbiosis remains challenging,
and the diagnostic constellation of hypocobalaminemia with concur-
rent hyperfolatemia should not be used as a justification for antibiotic
administration.
5 | TREATMENT
Cobalamin should be supplemented whenever serum cobalamin con-
centration is subnormal. There is a 12% probability that CIE dogs with
low-normal serum cobalamin concentration (ie, less than approxi-
mately 400 ng/L) might also benefit from supplementation.26,33
Cyanocobalamin has traditionally been used for supplementation, as it
is widely available and inexpensive. The possibility of
normocobalaminemia being restored in hypocobalaminemic dogs with
CIE when treating the underlying disease without supplementing
cobalamin has not been demonstrated.
In dogs with CIE and suboptimal cobalamin status, cobalamin is
recommended to be given at a dose of 50 μg/kg SC every 7 days or
50 μg/kg PO q24h.28,33 Current consensus is that over-
supplementation with cobalamin or cobalamin toxicity does not occur.
While this is a reasonable assumption based on theoretical consider-
ations, there are no data available in companion animals to support
this hypothesis. In people, chronic oversupplementation with cobala-
min might increase the risk for lung cancer in smokers.129,130 In dogs
with IGS, dosing intervals are highly variable with cobalamin injections
being done weekly, every other week, every 4 weeks, or bimonthly. In
1 case that was supplemented every 4-5 months, clinical signs and
methylmalonic aciduria returned.1 After starting cobalamin supple-
mentation, appetite and well-being of dogs with IGS can return to
normal within 12 to 48 hours74,87 and weight gain will follow over
days to weeks. Normalization of hematological abnormalities can take
up to 14 days.74,87 Urinary MMA excretion as well as the serum MMA
concentration can be expected to normalize (ie, decrease to within RI)
within a week of initiating cobalamin supplementation.17,74,87 How-
ever, proteinuria in dogs with selective cobalamin malabsorption will
persist lifelong due to abnormal renal tubular cubam function that is
not corrected by cobalamin supplementation.131 In people with IGS,
tubular proteinuria does not adversely affect renal function, and long-
term follow-up of affected human patients (up to 50 years) suggests
that renal prognosis is excellent.132
Dogs with selective cobalamin malabsorption—if left untreated—
will die as a result of metabolic derangements and immunodefi-
ciency.78,81,83,92 There is limited evidence-based information about
the optimum route, dose, and dosing interval of cobalamin supple-
mentation in dogs available. Currently either parenteral or oral cobala-
min supplementation is recommended:
5.1 | Parenteral cobalamin supplementation
5.1.1 | Protocol
Initially, weekly SC injections of 50 μg/kg SC cyanocobalamin
(250-1500 μg depending on the size of the dog; see Table S2) over a
period of 6 weeks, then an additional dose 1 month later, followed by
measurement of serum cobalamin concentration 1 month after the
last dose.33
5.1.2 | Monitoring
If the underlying disease process has resolved and cobalamin body
stores have been restored, serum cobalamin concentration should be
above the RI at the time of retesting. If serum cobalamin concentra-
tion is still within RI (ie, supranormal serum cobalamin concentrations
have not been achieved), cobalamin supplementation was traditionally
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recommended to be continued every 2-4 weeks. More than 90% of
dogs with a suboptimal serum cobalamin status achieve hyp-
ercobalaminemia within 4 weeks of parenteral cobalamin supplemen-
tation, but serum cobalamin concentrations decreased within the RI
towards the 12-week mark of cobalamin supplementation in the
majority of these dogs.28 In some dogs, serum cobalamin concentra-
tions are not adequate with cyanocobalamin supplementation, and
hydroxocobalamin might be more effective in these dogs (Steiner JM,
personal communication). However, monitoring serum MMA concen-
trations alone or in combination with serum cobalamin concentrations
might be a more appropriate way to reevaluate the canine cobalamin
status after treatment.59
A study investigating the effect of injectable hydroxocobalamin
for the treatment of Beagle dogs with IGS showed a dose of 1 mg
hydroxocobalamin administered IM to be adequate for maintaining a
normal clinical status and normal urine MMA concentrations for up to
2 months.59 Hydroxocobalamin is considered the treatment of choice
for children with IGS88,133,134 and other types of hereditary cobalamin
deficiency.135,136 It is likely more effective than cyanocobalamin
because this compound presents the natural form of cobalamin.137 In
addition, IM injections of hydroxocobalamin appear to cause less pain
than cyanocobalamin.134
5.2 | Oral cobalamin supplementation
5.2.1 | Protocol
Cobalamin (50 μg/kg PO) is administered once daily (250-1000 μg in
dogs, depending on the size of the dog; see Table S3) over a period of
12 weeks,33 followed by a recheck of serum cobalamin concentration
after discontinuation of supplementation. Dogs were rechecked the
day after the last PO cobalamin dose in this study,33 but the authors
typically recheck serum cobalamin concentration 1 week after the last
cobalamin tablet.
5.2.2 | Monitoring
Several studies in human patients with hypocobalaminemia suggest
that supplementation with oral cobalamin might be as effective as
parenteral administration.138-140 A study that included 51 dogs
showed that serum cobalamin concentrations increased significantly
and normocobalaminemia was achieved in all hypocobalaminemic
dogs with chronic enteropathy after daily oral cobalamin supplemen-
tation for at least 3 weeks (20-202 days).141 However, similar to this
study, another investigation by the same research group showed that
supranormal serum cobalamin concentrations were achieved in only
about half of the dogs. The dogs in this study reached normal serum
cobalamin concentrations within 4 weeks of receiving PO cobalamin,
but a hypercobalaminemic state was reached after 12 weeks of PO
cobalamin supplementation in about two thirds of these dogs.28 In
addition, other recent studies suggest that daily PO cobalamin supple-
mentation is effective to normalize the serum cobalamin status in
dogs with CIE and also to maintain normal cobalamin status in dogs
with hereditary cobalamin malabsorption that had previously been
supplemented with parenteral hydroxocobalamin.28,47 Thus, oral
cobalamin supplementation is a simple, noninvasive, and pain-free
alternative to weekly SC injections of either cyanocobalamin or
hydroxocobalamin.28,33 An alternative pathway of intestinal cobalamin
absorption beyond receptor-mediated transport in the ileum is a pos-
sible explanation why oral cobalamin supplementation might be effec-
tive in spite of a defective receptor-mediated uptake into enterocytes.
This has also been reported in people.11 However, expression levels
of the ileal cobalamin-IF receptor in dogs with chronic enteropathies
have not been investigated.
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